Time course and dose response of alpha tocopherol on oxidative stress in haemodialysis patients

BMC Nephrology

Volumn 10, Issue 1, 2009, Pages

  Reed, Ashleigh ^a   Cho, Yeoung Jee ^b   Coombes, Jeff S ^a   Fassett, Robert G ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ISOPROSTANE DERIVATIVE; PLACEBO;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; OBSERVATIONAL STUDY; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; BLOOD; CHRONIC KIDNEY FAILURE; DOSE RESPONSE; DRUG EFFECT; MIDDLE AGED; PHYSIOLOGY; RENAL REPLACEMENT THERAPY; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-TOCOPHEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; F2-ISOPROSTANES; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70450228618     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-10-32     Document Type: Article

References (28)

1. Oxidative stress in uremia. J Himmelfarb RM Hakim, Curr Opin Nephrol Hypertens 2003 12 6 593 598 10.1097/00041552-200311000-00004 14564195
2. Vitamin E consumption and the risk of coronary disease in women. MJ Stampfer CH Hennekens JE Manson GA Colditz B Rosner WC Willett, N Engl J Med 1993 328 20 1444 1449 10.1056/NEJM199305203282003 8479463 (Pubitemid 23143846)
3. Vitamin E consumption and the risk of coronary heart disease in men. EB Rimm MJ Stampfer A Ascherio E Giovannucci GA Colditz WC Willett, N Engl J Med 1993 328 20 1450 1456 10.1056/NEJM199305203282004 8479464
4. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. S Yusuf G Dagenais J Pogue J Bosch P Sleight, N Engl J Med 2000 342 3 154 160 10.1056/NEJM200001203420302 10639540
5. Why have antioxidants failed in clinical trials? SR Steinhubl, Am J Cardiol 2008 101 10A 14D 19D 10.1016/j.amjcard.2008.02.003 18474268
6. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. G de Gaetano, Lancet 2001 357 9250 89 95 10.1016/S0140-6736(00)03539-X 11197445
7. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 360 9326 23 33 10.1016/S0140-6736(02)09328-5 12114037
8. Angiotensin-converting enzyme (ACE) inhibition in the secondary prevention of vascular disease: the Heart Outcomes Prevention Evaluation (HOPE) Trial and its substudies. RA Hegele, Curr Atheroscler Rep 2000 2 5 361 362 10.1007/s11883-000-0073-5 11122766
9. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999 354 9177 447 455 10.1016/S0140-6736(99)07072-5 10465168
10. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). NG Stephens A Parsons PM Schofield F Kelly K Cheeseman MJ Mitchinson, Lancet 1996 347 9004 781 786 10.1016/S0140-6736(96)90866-1 8622332
11. The alpha-tocopherol, beta-carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. The ATBC Cancer Prevention Study Group. Ann Epidemiol 1994 4 1 1 10 8205268
12. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. J Himmelfarb P Stenvinkel TA Ikizler RM Hakim, Kidney Int 2002 62 5 1524 1538 10.1046/j.1523-1755.2002.00600.x 12371953
13. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. AS Levey JA Beto BE Coronado G Eknoyan RN Foley BL Kasiske MJ Klag LU Mailloux CL Manske KB Meyer, et al. Am J Kidney Dis 1998 32 5 853 906 10.1016/S0272-6386(98)70145-3 9820460
14. End-stage renal disease in the United States: an update from the United States Renal Data System. RN Foley AJ Collins, J Am Soc Nephrol 2007 18 10 2644 2648 10.1681/ASN.2007020220 17656472
15. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. M Boaz S Smetana T Weinstein Z Matas U Gafter A Iaina A Knecht Y Weissgarten D Brunner M Fainaru, et al. Lancet 2000 356 9237 1213 1218 10.1016/S0140-6736(00)02783-5 11072938
16. Vitamin E supplementation. A Gazis A Fogarty, Lancet 2001 357 9256 631 632 author reply 632-633. 10.1016/S0140-6736(05)71417-3 11558503
17. Vitamin E supplementation. SL Nuttall MJ Kendall JN Townend DC Wheeler, Lancet 2001 357 9256 631 author reply 632-633. 10.1016/S0140-6736(00)04070-8 11558504
18. Vitamin E supplementation. F Violi F Micheletta L Iuliano, Lancet 2001 357 9256 632 633 10.1016/S0140-6736(05)71418-5 11558505
19. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. DP Vivekananthan MS Penn SK Sapp A Hsu EJ Topol, Lancet 2003 361 9374 2017 2023 10.1016/S0140-6736(03)13637-9 12814711
20. Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. JF Mann EM Lonn Q Yi HC Gerstein BJ Hoogwerf J Pogue J Bosch GR Dagenais S Yusuf, Kidney Int 2004 65 4 1375 1380 10.1111/j.1523-1755.2004.00513.x 15086477
21. Author's reply. MS Boaz M S Green, Lancet 2001 357 9256 632 633 10.1016/S0140-6736(05)71419-7 11558505
22. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. G Bjelakovic D Nikolova LL Gluud RG Simonetti C Gluud, JAMA 2007 297 8 842 857 10.1001/jama.297.8.842 17327526
23. The relationship between dose of vitamin E and suppression of oxidative stress in humans. LJ Roberts 2nd JA Oates MF Linton S Fazio BP Meador MD Gross Y Shyr JD Morrow, Free Radic Biol Med 2007 43 10 1388 1393 10.1016/j. freeradbiomed.2007.06.019 17936185
24. Serum Concentrations of F2-Isoprostanes and 4-Hydroxynonenal in Hemodialysis Patients in Relation to Inflammation and Renal Anemia. I Wiswedel D Peter A Gardemann F Carluccio H Hampl W Siems, Biomark Insights 2008 3 419 428 19578522
25. F2-isoprostanes as biomarkers of lipid peroxidation in patients with chronic renal failure. I Wiswedel D Hirsch F Carluccio H Hampl W Siems, Biofactors 2005 24 1-4 201 208 10.1002/biof.5520240124 16403981
26. Benefits of prolonged gradient separation for high-performance liquid chromatography-tandem mass spectrometry quantitation of plasma total 15-series F-isoprostanes. AW Taylor RS Bruno B Frei MG Traber, Anal Biochem 2006 350 1 41 51 10.1016/j.ab.2005.12.003 16448621
27. An improved method for the measurement of urinary and plasma F2-isoprostanes using gas chromatography-mass spectrometry. TA Mori KD Croft IB Puddey LJ Beilin, Anal Biochem 1999 268 1 117 125 10.1006/abio.1998.3037 10036170
28. Novel HPLC analysis of tocopherols, tocotrienols, and cholesterol in tissue. E Katsanidis PB Addis, Free Radic Biol Med 1999 27 11-12 1137 1140 10.1016/S0891-5849(99)00205-1 10641704